008 decreased
20.7% to $1.2 million compared to the same period in 2007. Selling expenses
for the period increased to approximately $0.34 million from 0.15 million
in the first quarter of 2007, which is due to the Company's investment in
overall marketing. General and administrative expenses were $0.82 million
in the three months ended March 31, 2008, a decrease of $0.49 million, or
37.5% compared to the first quarter of 2007, with the improvement emanating
from the collection of bad debt reserves written-off in 2007, which
reinforces China Pharma's ability to collect customer receivables
Operating income for the first quarter of 2008 totalled $4.7 million, a
152.2% increase, compared to $1.8 million for the same period in 2007. Net
income was $4.2 million, representing an increase of 76.5% from $2.4
million reported in the same year ago period. Fully diluted earnings per
share were $0.11, a 57.1% increase from $0.07 in the first quarter of 2007.
"We are pleased to report another quarter of strong revenue and net
income growth. The success of our increased marketing efforts and
diversified portfolio focusing on therapeutics targeting high mortality and
high incidence diseases enabled us to achieve a 62% increase in revenues
for the first quarter of 2008," commented Ms. Zhilin Li, President and CEO
of China Pharma, "Our ability to prudently manage expenses while collecting
on 2007 bad debt reserves contributed to the decrease in operating expenses
and resulted in a higher operating margin. We anticipate this trend will
continue during 2008 as we aim to maintain or improve margins and
profitability going forward."
Balance Sheet and Cash Flow Discussion
The Company had Stockholders' equity of $45.7 million, representing a
book value of approximately $1.23 per diluted share as of March 31, 2008.
With the significant increase in revenues, trade accounts receivable grew
approximately 33.6%. The Company's outstanding receivables over 12 months
o
'/>"/>
SOURCE China Pharma Holdings, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 Related biology technology :1.
China Biologic Products Announces SFDA Approval for the Production of Cryoprecipitate and for the Clinical Trial of Human Prothrombin Complex2.
DuPont Partnering with China to Increase Farm Productivity3.
China Yingxia International, Inc. Acquires Grocery Chain and Online Distribution Network4.
China Sky One Medical, Inc. Acquires Heilongjiang Haina Pharmaceutical Inc.5.
Syngenta To Build Major Global Biotech Research Center in Beijing, China6.
American Oriental Bioengineering and China Aoxing Pharmaceutical Enter Into Strategic Alliance7.
China YCT International Group, Inc. Announces Entrusted Management Agreement With Its Primary Supplier8.
CTDC Attends the Inauguration Ceremony of Thin Film A-Si Manufacturing Line in Changzhou, China9.
China Bio Energy Reports Fiscal 2007 Financial Results10.
Transgenomic Opens Pharmacogenomics Laboratory in China11.
China Pharma Holdings, Inc. Announces Record 2007 Year End Results